IBI3017
/ Innovent Biologics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 21, 2026
Impact of IBI3017, an innovative bispecific anti-Trop2 and B7H3 antibody-drug conjugate, on anti-tumor efficacy in a wide range of tumors.
(ASCO 2026)
- "In summary, IBI3017 demonstrates promising potential for delivering potent and broad anti-tumor activity across a range of solid tumors, offering broad clinical application opportunities."
ADC • Bispecific • Clinical • Breast Cancer • Dental Disorders • Lung Cancer • Mucositis • Non Small Cell Lung Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • Stomatitis • CD276 • TACSTD2
1 to 1
Of
1
Go to page
1